Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Plakous Therapeutics Inc. is engaged in the Biotechnology & Pharmaceuticals technology area, where it has 1 pending office action. This activity is contained within 1 distinct art unit. This suggests a highly targeted technical focus for the company's current patenting efforts. This concentration indicates a strategic emphasis on a particular technical niche within the Biotechnology & Pharmaceuticals sector.
The portfolio is being examined by 1 distinct examiner. FOX, ALLISON M is the busiest examiner for Plakous Therapeutics Inc., handling 1 pending office action. This indicates that all current prosecution for the company is being handled by this individual. The use of 1 distinct examiner suggests a centralized review process where all communication is directed through this official, which simplifies the management of the portfolio.
The data reveals a focused prosecution profile with 1 pending office action and 1 distinct examiner. For practitioners, the fact that 1 distinct art unit is involved signifies a singular path for the company's current intellectual property development. Since FOX, ALLISON M handles 1 pending office action, the outcome depends on this individual's interpretation of the claims.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FOX, ALLISON M | 2 | 71.0% | +35.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18926116 | ACELLULAR PLACENTAL PREPARATIONS | FOX, ALLISON M | — |
| 17780173 | ACELLULAR PLACENTAL THERAPIES FOR NECROTIZING ENTEROCOLITIS | FOX, ALLISON M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18926116 | ACELLULAR PLACENTAL PREPARATIONS | FOX, ALLISON M | — |
| 17780173 | ACELLULAR PLACENTAL THERAPIES FOR NECROTIZING ENTEROCOLITIS | FOX, ALLISON M | — |
| Art Unit | Apps |
|---|---|
| 1633 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18926116 | ACELLULAR PLACENTAL PREPARATIONS | FOX, ALLISON M | 1633 | §101§102§103§112Other | Non-Final OA | — | Pending | Oct 24, 2024 |
| 17780173 | ACELLULAR PLACENTAL THERAPIES FOR NECROTIZING ENTEROCOLITIS | FOX, ALLISON M | 1633 | §101§102§103§112DP | Non-Final OA | — | Pending | May 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPlakous Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Allison M Fox has the most, with 2 of Plakous Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
